CYP2C9 and rheumatoid arthritis: Furthermore, polymorphisms in CYP2C9 considerably affect the pharmacokinetics and drug response variability of celecoxib, a medication used to treat osteoarthritis, rheumatoid arthritis, acute pain, and familial adenomatous polyposis.